Luminary is a clinical-stage gene modified cellular therapy development company. We expect to launch our first clinical trial in Q1-2022 with a novel 3 receptor Ligand CAR designed to overcome antigen escape. The primary focus of the company is superior cell engineered CAR’s and TCR’s designed to create cellular therapies that abate antigen escape and T-Cell exhaustion. Luminary was founded by the team from B-MoGen who developed TcBuster and had a successful 5X exit in three years. We are out seeking a Series A financing with either Venture firms or strategic alliances that will support our 1st clinical trial and the development of our disruptive U-Receptor CAR that can modulate antigen specifity.